Market Analysis Report
Market Analysis Report
复制标题
市场分析报告
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
O. Otroshi
中科院分区：
文献类型：
--
作者：
O. Otroshi
自身免疫性疾病是身体对正常存在于体内的物质和组织的过度活跃的免疫反应。自身免疫性疾病更常见于遗传、感染或环境因素。自身免疫性疾病的患病率正在上升。据估计，这些疾病是65岁以下妇女死亡的十大原因之一，也是慢性病的第二大原因。此外，它是美国女性发病的首要原因。迄今为止，已确定了80多种临床上不同类型的自身免疫性疾病。一些常见类型的自身免疫性疾病是克罗恩病、类风湿性关节炎、炎性肠病、多发性硬化症、系统性红斑狼疮，并且随着自身免疫性疾病患病率的上升，对用于治疗自身免疫性疾病的药物的需求也在上升。随着自身免疫性疾病发病率的上升，医疗领域的快速技术进步，如新型生物标志物，医疗保健支出的增加，东欧，亚太地区和MEA地区等新兴市场的开发和大量未开发机会的存在是主要因素，预计将促进全球自身免疫性疾病治疗市场在预测期内的增长（2017-2026）。全球自身免疫性疾病治疗市场预计将在预测期内实现健康的复合年增长率。根据地理区域的不同，全球自身免疫性疾病治疗市场分为七个主要地区：北美，南美，东欧，西欧和亚太地区（不包括日本，日本和中东及非洲）。北美在自身免疫性疾病治疗市场中占最大的市场份额，这是由于各种形式的自身免疫性疾病的患病率越来越高，以及政府举措的存在，如《平价医疗法案》和《患者保护法案》。预计该地区医疗保健支出的增加也将在不久的将来推动整体自身免疫性疾病治疗市场。根据美国国立卫生研究院的估计，每年用于自身免疫性疾病治疗的费用估计为1000亿美元。欧洲预计将成为预测期内的第二大市场，原因是政府越来越重视改善医疗基础设施，自身免疫性疾病的流行率不断上升，便携式诊断设备和新型生物标志物等新技术的渗透率不断提高。然而，在东欧，大量未开发的机会将在未来几年推动自身免疫性疾病治疗剂的市场增长。
An autoimmune disease is a body’s hyperactive immune response against the substances and tissues normally present in the body. Autoimmune diseases are more commonly caused by genetic, infectious or environmental factors. The prevalence of autoimmune disease is on rise. The diseases in estimated to be one of the top 10 cause of death in women under the age 65, and is the second highest cause of chronic illness. Also, it is the top cause of morbidity in women in the U.S. There are more than 80 clinically different type of autoimmune diseases identified till date. Some of the common types of autoimmune diseases are Crohn’s disease, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, and with rising prevalence of autoimmune diseases the demand of drugs used in the treatment for autoimmune disease is also rising. With rising incidence of autoimmune diseases, rapid technological advancements in medical field such as novel biomarkers, rise in healthcare expenditure, development and presence of large untapped opportunities in the emerging markets such as Eastern European, APAC and MEA region are major factors, expected to boost the growth of the global autoimmune disease therapeutics market during the forecast period (2017–2026). The global market for autoimmune disease therapeutics is expected to register a healthy CAGR during the forecast period. Depending on geographic regions, global autoimmune disease therapeutics market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan and Middle East & Africa. North America accounts for the largest market shares in the autoimmune disease therapeutics market owing to growing prevalence of various forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act. Increasing healthcare expenditure in the region is also expected to drive the overall autoimmune disease therapeutics market in the near future. According to National Institute of Health estimates in the U.S. the annual expenditure on autoimmune disease therapeutics is estimated to be US$ 100 Bn. Europe is anticipated to be the second largest market during the forecast period owing to increasing government with the focus of improving healthcare infrastructure, growing prevalence of autoimmune diseases, increased penetration of new technologies such as portable diagnostic equipment and novel biomarkers. However, in Eastern Europe presence of large untapped opportunities will fuel the market growth of autoimmune disease therapeutics in the coming years.